# Solventum Corporation (SOLV) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Medical Devices & Supplies. Price $84.76, market value $14.4 billion.

## Valuation
- **P/E (trailing): 10.4×** (5-yr avg 16.4×, 3-yr avg 16.4×). Solventum Corporation trades at 10.4× trailing earnings, well below its own five-year average of 16.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 11.7×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.05**. A PEG of 0.05 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.7×**. Each dollar of revenue is priced at 1.7×.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 7.2×**. Enterprise value is 7.2× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: -0.8%** (5-yr avg 3.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 9.6%**. The inverse of the P/E: 9.6% of the price is earned each year.

## Profitability
- **Gross margin: 54.7%**. Solventum Corporation keeps 54.7% of revenue after the direct cost of what it sells.
- **Operating margin: 25.0%**. 25.0% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 18.7%**. 18.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 30.8%**. 30.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 17.8%**. Return on all capital, debt included, is 17.8%: comfortably above what that capital costs.
- **Return on assets: 10.0%**. Each dollar of assets produces 10.0% of profit.

## Growth
- **Revenue growth (1 yr): 0.9%** (3-yr 0.8%/yr). Revenue grew 0.9% over the last year.
- **EPS growth (1 yr): 221.7%** (3-yr 4.5%/yr). Earnings per share rose 221.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.00**. Debt is 1.00 times equity, moderate leverage.
- **Net debt / EBITDA: 1.6×**. It would take 1.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 1.23** (quick 1.23). Current assets cover the next year's liabilities 1.23 times.
- **Altman Z-score: 2.58**. A Z-score of 2.58 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Solventum Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover Solventum Corporation; the consensus is buy, with an average price target of $94.69 (+12% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 22.8%** (YTD 7.0%, 3-mo -3.8%). The shares are up 22.8% over twelve months including dividends.
- **From 52-week high: -10.0%** (35.9% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.59** (volatility 30%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SOLV · Page: https://foliofundamentals.com/stocks/solv

Not investment advice.